Psychedelics and Antenatal Health: Systematic Review Insights

Introduction to the Review

A recent systematic review published on May 19, 2026, examines the effects of antenatal exposure to classic psychedelics on maternal and child health outcomes. This preprint, available on OpenAlex, is among the first to systematically assess the potential implications of psychedelic exposure during pregnancy. Although the findings are preliminary due to the preprint status and absence of citations, the review provides a foundational understanding of this critical issue.

Mechanisms and Context

Classic psychedelics, such as lysergic acid diethylamide (LSD) and psilocybin, are known to influence serotonin receptors, which play a crucial role in mood regulation and neurodevelopment. The review explores how these substances might impact fetal development and maternal health, considering factors such as dosage, frequency of use, and timing during pregnancy. The authors emphasize the need for a nuanced understanding of the biochemistry involved, as well as the social and psychological contexts of psychedelic use among pregnant individuals.

Research and Policy Implications

The review underscores the urgent need for more robust, peer-reviewed research to inform clinical guidelines and public health policies. Current data are insufficient to draw definitive conclusions about safety or efficacy, highlighting a significant gap in the literature. Policymakers and healthcare providers should be cautious in making recommendations until more comprehensive data are available. The potential therapeutic benefits of psychedelics in treating mental health conditions must be balanced against the unknown risks during pregnancy.

Risks and Unknowns

While the review identifies potential areas of concern, such as developmental delays or adverse maternal health outcomes, it also notes the lack of high-quality studies. The mixed sentiment of the review reflects both the promise of psychedelics in therapeutic settings and the potential risks they pose to vulnerable populations like pregnant women and their unborn children. The authors call for longitudinal studies and randomized controlled trials to better assess these risks.

Looking Forward

As the field of psychedelic research evolves, understanding the implications of antenatal exposure will be crucial. Researchers are encouraged to prioritize studies that explore both the short-term and long-term effects on child development and maternal health. Clinicians should remain informed about emerging data to guide their practice effectively. This review serves as a call to action for the scientific community to address these gaps and contribute to a more comprehensive understanding of psychedelics in antenatal care.